BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login
search help

Search Results

Documents 1-25 out of 45 found
  Current Search:  iressa: 45     

HTML
100%
Circulating tumor cells can reveal genetic signature of dangerous lung cancers
Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing...
Innovations Report:  Jul 5 2008 8:12AM
Matching: iressa
Find similar documents
HTML
100%
Motesanib Effective in Progressive Differentiated Thyroid Disease
July 4, 2008 The experimental drug motesanib (under development by Amgen) has shown activity in progressive advanced thyroid cancer in a phase 2 trial in 93 patients.

This is one of the largest clinical trials ever conducted in this...

Medscape:  Jul 4 2008 5:54PM
Matching: iressa
Find similar documents
HTML
100%
Circulating Tumor Cells Can Reveal Genetic Signature Of Dangerous Lung Cancers
A pilot study of the device called the CTC-chip will appear in the July 24 New England Journal of Medicine and is receiving early online release.

'The CTC-chip opens up a whole new field of studying tumors in real time,' says Daniel Haber,...

Science Daily:  Jul 4 2008 4:26AM
Matching: iressa
Find similar documents
HTML
100%
Promising New Tool to Monitor Lung Cancer Treatment Progress
Researchers at Massachusetts General Hospital (MGH) are testing a non-surgical technique that may help doctors monitor how well patients are responding to treatment.

Using a device known as a CTC-chip to analyze circulating tumor cells...

American Cancer Society:  Jul 3 2008 11:02PM
Matching: iressa
Find similar documents
HTML
100%
Circulating tumor cells can reveal genetic signature of dangerous lung cancers
Medicine & Health/ Cancer Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic...
PhysOrg.com:  Jul 3 2008 1:52PM
Matching: iressa
Find similar documents
HTML
100%
Microchip-based device determines the genetic signature of lung tumors
Massachusetts General Hospital (MGH)investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing...
News-Medical.Net:  Jul 3 2008 10:38AM
Matching: iressa
Find similar documents
HTML
100%
Report says cancer clinicians should understand and consider the economic impact of new interventions
Cancer clinicians should understand and consider the economic impact of new interventions, which often have substantial costs, according to a report appearing in the July/August issue of , a peer-reviewed journal of the.

The report says...

News-Medical.Net:  Jul 3 2008 1:13AM
Matching: iressa
Find similar documents
HTML
100%
Trapped Circulating Tumor Cells Track NSCLC Treatment
BOSTON, July 2 -- Patient response to non-small-cell lung cancer treatment can be assessed by capturing circulating tumor cells with a microchip, a small study showed.

Genotyping the cells had a sensitivity of 92% for mutations that affect...

MedPage Today:  Jul 2 2008 10:40PM
Matching: iressa
Find similar documents
HTML
100%
Circulating tumor cells can reveal genetic signature of dangerous lung cancers
, 6:05 PM EST (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing identification of...
Genetic Engineering News:  Jul 2 2008 10:21PM
Matching: iressa
Find similar documents
HTML
100%
Cancer Treatment Clinicians Should Consider Economic Impacts
Cancer clinicians should understand and consider the economic impact of new interventions when considering cancer treatment, which often have substantial costs, according to a report appearing in the July/August issue of CA: A Cancer Journal...
EMax Health:  Jul 2 2008 2:15PM
Matching: iressa
Find similar documents
HTML
100%
Report says clinicians should consider economic impact of new interventions
Cancer clinicians should understand and consider the economic impact of new interventions, which often have substantial costs, according to a report appearing in the July/August issue of CA: A Cancer Journal for Clinicians, a peer-reviewed...
Genetic Engineering News:  Jul 2 2008 4:29AM
Matching: iressa
Find similar documents
HTML
100%
A New Citeline Analysis Provides Valuable Clues To Health Of Drug Companies
In a new Expert Analysis article published in the July issue of GCPj, Tracy DeGregorio and Christine Blazynski examine the robustness of the leading pharma and biotech pipelines with respect to ongoing clinical trials activity, and find that...
Pharmaceutical Online:  Jul 1 2008 10:05AM
Matching: iressa
Find similar documents
HTML
100%
A New Citeline Analysis Provides Valuable Clues to Health of Drug Companies
NEW YORK, June 30 /PRNewswire/ -- In a new Expert Analysis article published in the July issue of GCPj, Tracy DeGregorio and Christine Blazynski examine the robustness of the leading pharma and biotech pipelines with respect to ongoing...
Portland Business Journal:  Jun 30 2008 5:21PM
Matching: iressa
Find similar documents
HTML
100%
A New Citeline Analysis Provides Valuable Clues to Health of Drug Companies
NEW YORK, June 30 /PRNewswire/ -- In a new Expert Analysis article published in the July issue of GCPj, Tracy DeGregorio and Christine Blazynski examine the robustness of the leading pharma and biotech pipelines with respect to ongoing...
The Business Journal Phoenix:  Jun 30 2008 5:20PM
Matching: iressa
Find similar documents
HTML
100%
A New Citeline Analysis Provides Valuable Clues to Health of Drug Companies
NEW YORK, June 30 /PRNewswire/ -- In a new Expert Analysis article published in the July issue of GCPj, Tracy DeGregorio and Christine Blazynski examine the robustness of the leading pharma and biotech pipelines with respect to ongoing...
Biz Journals:  Jun 30 2008 5:09PM
Matching: iressa
Find similar documents
HTML
100%
A New Citeline Analysis Provides Valuable Clues to Health of Drug Companies
NEW YORK, June 30 /PRNewswire/ -- In a new Expert Analysis article published in the July issue of GCPj, Tracy DeGregorio and Christine Blazynski examine the robustness of the leading pharma and biotech pipelines with respect to ongoing...
Nashville Business Journal:  Jun 30 2008 5:07PM
Matching: iressa
Find similar documents
HTML
100%
A New Citeline Analysis Provides Valuable Clues to Health of Drug Companies
In a detailed ranking of companies by ongoing trial activity across six therapeutic areas (autoimmune/inflammation, cardiovascular, CNS, metabolic, infectious diseases, and oncology), this analysis finds that those companies spending in...
NewsBlaze:  Jun 30 2008 5:06PM
Matching: iressa
Find similar documents
HTML
100%
20 Compounds That Defined Biotech
As we know all too well, the course of a drug candidates clinical development is almost never smooth, and can often be pitted with unanticipated obstacles.

Yet, despite this, many drugs manage to not only receive the FDAs blessing, but...

Signals Magazine:  Jun 27 2008 7:50PM
Matching: iressa
Find similar documents
HTML
100%
OSI shares rise on Weisel 'Overweight' rating
Tarceva, which is approved to treat non-small cell lung cancer and pancreatic cancer and was developed by OSI, is sold by Genentech Inc.

Analyst Stephen Willey said Tarceva sales could get a boost from data expected in the second half of...

Yahoo! Canada:  Jun 27 2008 4:33PM
Matching: iressa
Find similar documents
HTML
100%
OSI shares rise after Thomas Weisel initiates 'Overweight' rating, citing Tarceva sales
OSI shares rise after Thomas Weisel initiates 'Overweight' rating, citing Tarceva sales NEW YORK (AP) - Shares of OSI Pharmaceuticals Inc.

rose Friday after a Thomas Weisel Partners analysts initiated coverage of the biopharmaceutical...

Canadian Business Magazine:  Jun 27 2008 4:32PM
Matching: iressa
Find similar documents
HTML
100%
OSI shares rise on Weisel 'Overweight' rating
Shares of OSI Pharmaceuticals Inc.

rose Friday after a Thomas Weisel Partners analysts initiated coverage of the biopharmaceutical company with an 'Overweight' rating, citing accelerating sales of the cancer drug Tarceva.

Tarceva, which...

Forbes.com:  Jun 27 2008 4:20PM
Matching: iressa
Find similar documents
HTML
100%
OSI shares rise on Weisel 'Overweight' rating
NEW YORK - Shares of OSI Pharmaceuticals Inc.

rose Friday after a Thomas Weisel Partners analysts initiated coverage of the biopharmaceutical company with an 'Overweight' rating, citing accelerating sales of the cancer drug Tarceva.

CNBC:  Jun 27 2008 4:18PM
Matching: iressa
Find similar documents
HTML
100%
Pharmaceutical Pricing and Distribution in Japan Incorporates All Pricing Rule Changes That Came into Effect f
4:10 PM ET DUBLIN, Ireland--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/b2dd9e/pharmaceutical_pri) has announced the addition of the 'Pharmaceutical Pricing and Distribution in Japan: The keys to...
Business Week:  Jun 18 2008 11:43AM
Matching: iressa
Find similar documents
HTML
100%
Pharmaceutical Pricing and Distribution in Japan Incorporates All Pricing Rule Changes That Came into Effect f
DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/b2dd9e/pharmaceutical_pri) has announced the addition of the 'Pharmaceutical Pricing and Distribution in Japan: The keys to success in the...
Business Wire via Yahoo!:  Jun 18 2008 10:42AM
Matching: iressa
Find similar documents
HTML
100%
M. D. Anderson and Aureon Laboratories to Evaluate Biomarkers Associated with Non-Small Cell Lung Cancer
Business Editors/Health/Medical Writers Aureon's systems pathology platform applies morphometric imaging to formalin-fixed, paraffin-embedded (FFPE) tissue specimens, enabling quantitation and integration of histological attributes and...
Macro World Investor:  Jun 10 2008 7:06PM
Matching: iressa
Find similar documents

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.